Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.
12:45 PM - 1:00 PM (PDT), Monday, June 13, 2022
Atom Bioscience is a Chinese biotech focused on discovery and development of best in class small molecule therapeutics for metabolic and inflammatory disease. Our lead development program is ABP-671, a second generation URAT1 inhibitor for treatment of gout. Phase 2a study was completed in Australia and pivotal phase 2b/3 study is planned to start in the US in the second half of 2022. We will be meeting with the FDA and obtain confirmation of our phase 2b/3 pivotal study shortly.
Additional pipeline products include Xanthine Oxidase inhibitor for gout, a new drug to treat acute gout and a new drug for NASH which are all in pre-clinical development with IND targeted in 12 - 18 months.
Atom Bioscience has raised ove $87 million to date including a Series C round for $47 million which was completed in Dec. 2021.
Additional pipeline products include Xanthine Oxidase inhibitor for gout, a new drug to treat acute gout and a new drug for NASH which are all in pre-clinical development with IND targeted in 12 - 18 months.
Atom Bioscience has raised ove $87 million to date including a Series C round for $47 million which was completed in Dec. 2021.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
ABP-671, URAT1 inhibitor for gout
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
